Recombinant Human KHK protein

中文名： 酮己糖激酶(KHK)重组蛋白
别名： KHK;Ketohexokinase

货号: PA1000-1716

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>90%SDS-PAGE.
种属	Human
靶点	KHK
Uniprot No	P50053
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	1-298aa
氨基酸序列	MEEKQILCVGLVVLDVISLVDKYPKEDSEIRCLSQRWQRGGNASNSCTVLSLLGAPCAFMGSMAPGHVADFVLDDLRRYSVDLRYTVFQTTGSVPIATVIINEASGSRTILYYDRSLPDVSATDFEKVDLTQFKWIHIEGRNASEQVKMLQRIDAHNTRQPPEQKIRVSVEVEKPREELFQLFGYGDVVFVSKDVAKHLGFQSAEEALRGLYGRVRKGAVLVCAWAEEGADALGPDGKLLHSDAFPPPRVVDTLGAGDTFNASVIFSLSQGRSVQEALRFGCQVAGKKCGLQGFDGIV
预测分子量	59.7kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是关于KHK(酮己糖激酶)重组蛋白的3篇模拟参考文献及摘要概括：

1. **文献名称**：*"Expression and Characterization of Recombinant Human Ketohexokinase in Escherichia coli"*

**作者**：Smith J. et al.

**摘要**：该研究成功在大肠杆菌中表达了可溶性人源KHK重组蛋白，通过优化表达条件及纯化步骤获得高纯度蛋白。酶动力学分析表明重组KHK对果糖具有高催化活性，为后续酶学机制研究提供了基础。

2. **文献名称**：*"Crystal Structure of Ketohexokinase Reveals Insights into Substrate Recognition"*

**作者**：Chen L. et al.

**摘要**：本研究解析了重组KHK的晶体结构，揭示了其与果糖结合的活性位点及关键氨基酸残基，阐明了KHK底物特异性的结构基础，为开发代谢疾病相关抑制剂提供了理论依据。

3. **文献名称**：*"Role of Recombinant KHK Isoforms in Fructose-Induced Metabolic Dysregulation"*

**作者**：Wang Y. et al.

**摘要**：通过比较重组KHK-A和KHK-C两种亚型的活性，发现KHK-C在肝脏中主导果糖代谢，且其过度激活与脂肪肝和胰岛素抵抗相关，提示KHK亚型选择性调控在代谢疾病中的潜在价值。

(注：以上文献信息为模拟生成，实际研究需查阅具体数据库。)

背景信息

**Background of KHK Recombinant Proteins**

Ketokexokinase (KHK), also known as fructokinase, is a metabolic enzyme that plays a critical role in fructose metabolism. It catalyzes the phosphorylation of fructose to fructose-1-phosphate, a rate-limiting step in the utilization of dietary fructose. Unlike glucose, fructose metabolism bypasses key regulatory checkpoints, making KHK activity pivotal in linking excessive fructose intake to metabolic disorders such as insulin resistance, fatty liver disease, and obesity.

Recombinant KHK proteins are engineered versions of this enzyme, produced using biotechnological systems like *E. coli*, yeast, or mammalian cell cultures*. These systems enable large-scale production of purified, functional KHK for research and therapeutic applications. Recombinant technology allows precise control over protein variants, including isoforms (KHK-A and KHK-C), which differ in tissue distribution and enzymatic activity. KHK-C, the dominant isoform in the liver, exhibits higher catalytic efficiency, whereas KHK-A, expressed in non-hepatic tissues, may have non-catalytic roles.

The development of KHK recombinant proteins has advanced studies on fructose metabolism and its pathological implications. Researchers use these proteins to investigate enzyme kinetics, substrate specificity, and interactions with inhibitors, aiding drug discovery for metabolic diseases. Additionally, recombinant KHK serves as a tool to explore genetic mutations linked to rare disorders like essential fructosuria, characterized by impaired fructose metabolism.

Recent interest in KHK inhibitors as potential therapeutics for obesity and non-alcoholic steatohepatitis (NASH) has further driven demand for high-quality recombinant KHK. Structural studies using these proteins have elucidated mechanisms of catalysis and regulation, informing targeted therapies. Overall, KHK recombinant proteins are vital for understanding fructose-driven metabolic dysregulation and developing interventions to mitigate associated health risks.

*(400 words)*